Industry

DUBLIN–(BUSINESS WIRE)–The “Wheelchairs Market, by Product Type and Electronic Wheelchair, by Weight, by Modality, by End-user, and by Region – Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030” report has been added to ResearchAndMarkets.com’s offering. Wheelchairs are primarily designed for disabled individuals for the ease of indoor and outdoor locomotion purposes. Various types of … [Read more…]

Eligible members will pay $0 out of pocket for preferred short and long-acting insulins and emergency use drugs that are critical in acute, life-saving circumstances Action is part of ongoing UnitedHealth Group efforts to improve access and make prescription drugs more affordable for people MINNETONKA, Minn.–(BUSINESS WIRE)–UnitedHealthcare will eliminate out-of-pocket costs in standard fully insured … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “U.S. Digital Therapeutics Market – Industry Outlook and Forecast 2022-2027” report has been added to ResearchAndMarkets.com’s offering. Digital therapeutics plays a significant role in the treatment and disease management of various chronic and mental health conditions. It presents potential solutions for chronic disease management, ranging from congestive heart failure, type 2 diabetes, Alzheimer’s … [Read more…]

A leader in the North American business services industry was recently added to one of the premier tradable global sustainability index funds CINCINNATI–(BUSINESS WIRE)–$CTAS–Cintas Corporation (Nasdaq: CTAS) has been included on the FTSE4Good Index. Created by the global index and data provider FTSE Russell, the FTSE4Good Index Series is designed to measure the performance of … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Pharmacovigilance World 2022” conference has been added to ResearchAndMarkets.com’s offering. With the augmented incidence of diseases, and the non-medical use of prescription drugs, the incidence of drug abuse has increased enormously in recent years, which is apparent with the excess documentation of adversities and drug toxicities. In this context, drug safety and pharmacovigilance … [Read more…]

Reflects continued progress in the business combination process; transaction is expected to be completed during the second half of 2022 SAN DIEGO & NORCROSS, Ga.–(BUSINESS WIRE)–Viveon Health Acquisition Corp. (NYSE: VHAQ) (“Viveon Health” or “VHAQ”), a special purpose acquisition company, and Suneva Medical, Inc. (“Suneva” or the “Company”), an innovative medical technology company using regenerative … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Pharmacy Benefit Management Market in the US – Industry Outlook & Forecast 2022-2027” report has been added to ResearchAndMarkets.com’s offering. The U.S. pharmacy benefit management market is expected to grow at a CAGR of 5.53% during 2022-2027 The study considers a detailed scenario of the present U.S. pharmacy benefit management market and its … [Read more…]

BOSTON–(BUSINESS WIRE)–Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it has named Chris Morabito, M.D., as Chief Medical Officer. Dr. Morabito brings more than 20 years of clinical development experience in rare diseases and other … [Read more…]

Enhances alignment with US shareholder base and other peer biotechnology companies Positions company for growth while helping to reduce complexity and certain administrative costs The Company’s name, brand, and ticker symbol to remain unchanged VANCOUVER, British Columbia & SEATTLE–(BUSINESS WIRE)–Zymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today … [Read more…]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the company will present new data that highlight the development of its highly selective, context-dependent TGFβ1 antibody that inhibits proTGFβ1 activation selectively in the context … [Read more…]